Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.62 |
| ▸ | BLK | P51451 | 1/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.62 |
| ▸ | STK3 | Q13188 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.59 |
| ▸ | PDE5A | O76074 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395013 | 1.00 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3587569 | 0.98 | TGFBR1 (0.69) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3578585 | 0.92 | TGFBR1 (0.65) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3586914 | 0.92 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3589215 | 0.92 | TGFBR1 (0.65) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL882717 | 0.91 | ROCK2 (0.69) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL31484231 | 0.90 | ROCK2 (0.70) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL26389170 | 0.90 | ROCK2 (0.70) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3585254 | 0.89 | ABCG2 (0.67) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL5140214 | 0.89 | TGFBR1 (0.62) | TGFBR1ROCK2ROCK1CLK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024023276-A1 | ROCK2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS | GRAVITON BIOSCIENCE BV (NL) | 2024-02-01 | — | — | WO | disclosed |
| US-20100249159-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-09-30 | — | — | US | disclosed |
| US-20100249159-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-09-30 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
| US-7645878-B2 | Reacting an aniline derivative with an acylchloride to form an intermeidate, cyclizing the intermediate, replacing hydroxy group with a leaving group (chloride), racting the product with an amino-heterocyclic compound | BAYER HEALTHCARE LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645878-B2 | Reacting an aniline derivative with an acylchloride to form an intermeidate, cyclizing the intermediate, replacing hydroxy group with a leaving group (chloride), racting the product with an amino-heterocyclic compound | BAYER HEALTHCARE LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1953152-A1 | Process for preparing quinazoline RHO-kinase inhibitors and intermediates thereof | Bayer Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1370552-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | TGFBR1 1599/4885ROCK2 3/4885ROCK1 2/4885 |
| US-20100249159-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | TGFBR1 1599/4885ROCK2 3/4885ROCK1 2/4885 |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | ROCK1, ROCK2, CIT | TGFBR1 4415/4885ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.